Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05899335
Other study ID # SCP001
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date November 2023
Est. completion date October 2025

Study information

Verified date August 2023
Source University of Dublin, Trinity College
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients with chronic pancreatitis suffer from constant debilitating symptoms. They have complex needs and require specialist, multi-disciplinary care. The investigators have developed a mobile phone app for patients with chronic pancreatitis, called the SmartCP app - the first app of its kind for this patient group. What is SmartCP? SmartCP is an app that allows patients to log daily symptoms, diet, and physical activity for review at clinic. It creates a red-alert for action if there are worsening symptoms. A Monthly-Check-In feature looks for symptoms of new diabetes or pancreatic cancer. SmartCP provides education on every aspect of pancreatitis, as well as contact information for the clinical team and for important pancreatitis resources. To develop SmartCP, the investigators established a multidisciplinary steering committee. The study The investigators aim to conduct a feasibility study to determine if the SmartCP app is feasible in the management of patients with chronic pancreatitis, complementing current specialist healthcare. Specifically, they will investigate acceptability, retention, incidents, resources, app user statistics, as well as investigating the occurrence of crisis events, symptoms, escalating symptoms, new diagnoses of diabetes or pancreatic cancer, and the use of communication and education features.


Description:

Background and rationale Chronic pancreatitis is an inherently complex disease requiring coordinated, multidisciplinary care. Patients suffer from constant, distressing, adverse symptoms including abdominal pain, steatorrhoea, bloating, wind, cramping, and fatigue - making it difficult to eat a normal or sufficient diet. They develop vitamin deficiencies, osteoporosis, and a difficult-to-manage diabetes subgroup (type 3c diabetes). There is no effective medical/surgical treatment, and the disease is progressive and incurable. The mainstay of treatment is diet, supplementation, and pancreatic enzyme replacement therapy- which helps patients to digest and absorb their food, alleviating symptoms somewhat. Contrary to perceptions, half of patients (or fewer) have an alcohol related aetiology. The investigators run several out-patient clinics for chronic pancreatitis including medical-led, nurse-specialist led, and type 3c diabetes clinics. A nurse specialist deal with 3-5 crisis phonically daily, each lasting up to 30mins. Patients have frequent urgent clinic attendance, A&E, and hospital admissions. What is the intervention? A steering group designed and developed the SmartCP mobile phone app during 2022 with the support of a government innovation grant. SmartCP consists of a symptom tracker, diet/physical activity log, alert system for escalating symptoms, quality of life assessment, red-flag alerts for diabetes/pancreatic cancer, educational content, push notifications and messaging function. Overall aim of the study To conduct a study to determine if SmartCP is feasible in the management patients with chronic pancreatitis, complementing current specialist clinical care. Design A single-arm, unblinded, feasibility study, with an uncontrolled, within-group baseline and post-intervention (16-week) design, with an embedded quantitative and qualitative process evaluation. Participants will receive the intervention for 16 weeks, supplementing usual clinical practice.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 30
Est. completion date October 2025
Est. primary completion date October 2024
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Reside in Ireland - Can read/write in English - Have daily access to compatible smartphone - Have daily access to home internet Exclusion Criteria: - Reside outside Ireland - Acutely unwell - Has multi-morbidity - Is current inpatient - Has prognosis <6months - Has pancreatic cancer - Is <18 years - Has no access to compatible smartphone - Has no access to home internet - Cannot read/write in English - Is unwilling/unable to provide informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Device:
SmartCP (mobile phone app)
As described

Locations

Country Name City State
Ireland University of Dublin, Trinity College Dublin

Sponsors (1)

Lead Sponsor Collaborator
University of Dublin, Trinity College

Country where clinical trial is conducted

Ireland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility: Recruitment The number of participants that are recruited versus the number eligible for recruitment 16 weeks
Primary Feasibility: Acceptability Acceptability of intervention (Telehealth Usability Questionnaire; 21 questions with scale of 1 to 7 for each question, with higher scores indicating more positive results) 16 weeks
Primary Feasibility: Retention Retention: Number of participant who continue to use SmartCP by the end of the intervention 16 weeks
Primary Feasibility: Incidents Number of adverse events reported by patients 16 weeks
Primary Feasibility: User statistics Minutes per day spent on the app during the intervention period 16 weeks
Primary Feasibility: User statistics Number per day of unique log-ins to the app during the intervention period 16 weeks
Secondary Occurrence of crisis events: Crisis phone-calls Number of crisis phone-calls per day to Tallaght University Hospital Advanced Nurse Practitioner 16 weeks
Secondary Occurrence of crisis events: Accident & Emergency Number of attendances per week at Accident & Emergency Room in any hospital 16 weeks
Secondary Occurrence of crisis events: Urgent clinic Number of urgent out-patient clinic attendances per week in Tallaght university Hospital 16 weeks
Secondary Symptoms: The nature and frequency of each symptom recorded using the daily symptoms tracker while using the app Recording of tiredness or lack of energy, steatorrhoea, loss of appetite, nausea, vomiting, dyspepsia, bloating or stomach distention, excess wind or flatulence - all according to the following scale: none, mild, moderate, severe 16 weeks
Secondary Symptoms: Number of Alerts created by the app The number of alerts created by the app in response to escalating symptoms requiring a phone-call or clinic attendance 16 weeks
Secondary Symptoms: Number of Red-Flag alerts created by the app The number of Red-flag alerts for possible new pancreatic cancer symptoms; red-flag alert for possible new diabetes symptoms 16 weeks
Secondary Quality of life (QoL): Short Form-12 Change in QoL scores measured by Short Form-12; Scores range from 0-100, with higher scores indicating better QoL 16 weeks
Secondary Quality of life (QoL): EQ-5D Changes in QoL measured by EQ-5D, a self-reported questionnaire that describes a respondent's health using a descriptive system comprised of five items, each representing a different health dimension (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each dimension, respondents state whether they have no problems, slight problems, moderate problems, severe problems, or are unable to perform the activity. Score range is 0-100. Higher scores indicate better QoL 16 weeks
Secondary Hospitalisation: Number of admissions Number of admissions to any hospital during the intervention period 16 weeks
Secondary Hospitalisation: Length of hospital stay Length of hospital stay at any hospital during the intervention period 16 weeks
Secondary Use of communications features: Number of times per week patients use app communications features Number of times per week that patients use the communication features on app (messaging the Advanced Nurse Practitioner via the app with a query) 16 weeks
Secondary Use of educational features: Number of times per week patients view app educational/informational features Number of times per week patients view various videos, graphic videos, read educational texts, click on new education features provided 16 weeks
See also
  Status Clinical Trial Phase
Completed NCT03112759 - Assessing the Utility of Cognitive Behavioral Therapy for Pain Control in Patients With Chronic Pancreatitis N/A
Enrolling by invitation NCT05410795 - Establishment and Verification of Pancreatic Volume Formula Based on Imaging
Active, not recruiting NCT02965898 - The Effect of Vitamin D Substitution on the Development of Chronic Pancreatitis N/A
Completed NCT01452217 - Non-invasive MRI to Quantify the Effect of Secretin on Pancreatic Blood Flow and Perfusion in Healthy Volunteers Phase 1
Completed NCT02868047 - Establishing Standards for Normal Pancreatic EUS N/A
Completed NCT00685087 - A Prospective Study of Natural History of Pancreatitis N/A
Completed NCT04949828 - Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms
Recruiting NCT06068426 - Incorporating Endoscopic Ultrasound and Elastography Towards Improving Outcomes of Pediatric Pancreatitis Management N/A
Active, not recruiting NCT05042284 - Effect of Non-enteric Coated Enzymes Substitution on Pain in Patients With Chronic Pancreatitis N/A
Active, not recruiting NCT05764629 - An Observational Study on Post-chronic Pancreatitis Diabetes Mellitus
Completed NCT03850977 - Is There an Association Between Chronic Pancreatitis and Pulmonary Function
Recruiting NCT05692596 - The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
Recruiting NCT06015945 - Role of Home-based Transcutaneous Electrical Acustimulation for Treatment of Pain in Patients With Chronic Pancreatitis N/A
Completed NCT04619511 - Risk Factors for Post-ESWL and Post-ERCP Pancreatitis
Completed NCT03283566 - Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing TPAIT Phase 2
Recruiting NCT03434392 - QST Study: Predicting Treatment Response in Chronic Pancreatitis Using Quantitative Sensory Testing N/A
Completed NCT01318369 - Efficacy Study of Δ9-THC to Treat Chronic Abdominal Pain Phase 2
Completed NCT01430234 - Enzyme Suppletion in Exocrine Pancreatic Dysfunction Phase 4
Terminated NCT01442454 - Endoscopic Ultrasound (EUS) Features of Chronic Pancreatitis N/A
Completed NCT00755573 - Pain and Chronic Pancreatitis - Clinical End Experimental Studies Phase 2/Phase 3